Timothy D. Ardizzone, Ph.D. | Associate
Practice Areas: Categories: Biotech, Chemicals/Materials Science, Patents
“My clients range from individuals with little technical training to scientists with advanced degrees. My varied background, which includes service in the military as well as years spent as a research scientist in academia, allows me to connect with all of my clients and to understand their various needs.”
Dr. Timothy D. Ardizzone concentrates his practice in patent prosecution, opinion work, post issuance review, and litigation in the fields of biotechnological innovations, medical devices and implants, chemical processes, laboratory equipment, alternative energy projects, and basic mechanical devices. Tim also works with trademark matters including prosecuting applications, providing clearance opinions, and protecting client’s interests in their trademarks and their use of marks in commerce.
The Court of Appeals for the Federal Circuit
The United State Patent and Trademark Office
The U.S. District Court for the Southern District of Ohio
University of Cincinnati College of Law, J.D., (Edmund P. Wood Law Scholarship, Robert W. Kershner Scholarship, College of Law Honors Scholarship, University of Cincinnati Law Review; Articles Editor, Dean’s List, Secretary of the Intellectual Property Legal Society)
Louisiana State University Health Sciences Center, Doctor of Philosophy, Department of Pharmacology and Therapeutics (Dissertation: Pharmacological Regulation of Glucose Transport in PC12 Cells)
Tulane University, B. S., Cell and Molecular Biology
Ohio State Bar Association
Cincinnati Bar Association
Serves as the President of the Board of the Science and Engineering Fair of Northern Kentucky (SEFNK), a non-profit organization that promotes early science education in children through a regional science fair and outreach in schools in a twenty-five county region in northern Kentucky.
Universities (UC, OU, OSU, UNR, U of L), large corporations, individual inventors, and start-ups.
CBA IP Litigation Group presentation, Differing standards for patentability and infringement of product-by-process claims, November 2009.
Ardizzone, T. D., Zhan, X., Ander, B. P., and Sharp, F. R. Src Kinase Inhibition Improves Acute Outcomes After Experimental Intracerebral Hemorrhage. Stroke, 38:1621, 2007.
Ardizzone, T. D. Comment: The FDA: Advocate or Regulator of the Pharmaceutical Industry? The Attempted Preemption by the FDA of State Tort Claims for Failure to Warn on Pharmaceutical Labeling. U. Cin. L. Rev., 75:3, 2007.
Lu, A., Tang, Y., Ran, R., Ardizzone, T. D., Wagner, K. R., and Sharp, F. R. Brain genomics of intracerebral hemorrhage. J. Cereb. Blood Flow Metab., 26:230, 2005.
Ardizzone, T. D., Lu, A., Wagner, K. R., Tang, Y., Ran, R., and Sharp, F. R. Glutamate receptor blockade attenuates glucose hypermetabolism in perihematomal brain after experimental intracerebral hemorrhage in rat. Stroke. 35:2587, 2004.
Sharp, F. R., Ran, R., Lu, A., Tang, Y., Strauss, K. I., Glass, T., Ardizzone, T., and Bernaudin, M. Hypoxic preconditioning protects against ischemic brain injury. J. Am. Soc. Exp. Neurotherapeutics. 1:26, 2004.
Wagner, K. R., Sharp, F. R., Ardizzone, T., Lu, A., and Clark, J. Heme and iron metabolism: Role in cerebral hemorrhage. J. Cereb. Bld. Flow Metab. 23:629, 2003.
Dwyer, D. S. and Ardizzone, T. D. Mimicry of dimerization by synthetic peptides designed to target homologous regions of proteins. Proteomics. 3:317, 2003.
Dwyer, D. S., Ardizzone, T. D., and Bradley, R. J. Psychotropic drugs affect glucose transport and the expression of glucose transporter (GLUT) proteins in neuronal cells. Int. Rev. Neurobiol. 51:503, 2002.
Ardizzone, T.D. and Dwyer, D.S. Inhibition of neuronal glucose transport by calcium channel antagonists. Rec. Res. Develop. Neurochem. 5:103, 2002.
Ardizzone, T. D., Bradley, R. J., and Dwyer, D. S. Calcium-independent inhibition of glucose transport in PC12 and L6 cells by calcium-channel blockers. Am. J. Physiol. 283:C579, 2002.
Ardizzone, T. D., Bradley, R. J., Freeman III, A. M., and Dwyer, D. S. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogues of clozapine. Brain Res. 923:82, 2001.
CBA IP Litigation Group presentation, The Myriad Case: The Supreme Court’s Attempt to Clarify Patentable Subject Matter, July 2013.